<DOC>
	<DOCNO>NCT02522715</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose cabazitaxel give together enzalutamide treat patient prostate cancer spread place body ( metastatic ) respond treatment hormone ( hormone-resistant ) . Drugs use chemotherapy , cabazitaxel , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Androgen cause growth prostate cancer cell . Hormone therapy use enzalutamide may fight prostate cancer block use androgen tumor cell . Giving cabazitaxel together enzalutamide may work well treat metastatic , hormone-resistant prostate cancer .</brief_summary>
	<brief_title>Enzalutamide Cabazitaxel Treating Patients With Metastatic , Hormone-Resistant Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety tolerability combination treatment enzalutamide cabazitaxel ( determined percent dose limit toxicity ( DLT ) , DLT &lt; 17 % consistent tolerable combination ) . II . To determine efficacy treatment hormonal agent enzalutamide chemotherapy cabazitaxel combination men metastatic castration-resistant prostate cancer ( CRPC ) ( determined percent patient achieve &gt; = 90 % prostate specific antigen ( PSA ) decline follow initiation treatment ) . SECONDARY OBJECTIVES : I . To define anticancer effect safety profile combination enzalutamide cabazitaxel . II . Collect toxicity data ( description adverse event ) . III . Determine PSA response ( percent patient achieve &gt; = 50 % PSA decline &gt; = 30 % PSA decline ) . IV . Examine pharmacokinetic ( PK ) data cabazitaxel characterize enzalutamide cabazitaxel pharmacokinetic blood level . V. Determine tumor response Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 measurable disease Prostate Cancer Working Group 2 criterion non-measurable ( bone ) disease . VI . Determine overall survival . TERTIARY OBJECTIVES : I . To determine baseline ( progression ) biological tumor characteristic evaluate possible biomarkers indicative predictive response : apoptosis cleave caspase 3 ; androgen signal axis ( include limit : androgen receptor expression , androgen receptor splice variant , intratumoral androgen level ) , glucocorticoid receptor . II . To collect circulate tumor cell ( CTCs ) determine degree tumor characteristic ( delineate ) share CTCs . III . To collect plasma serum pre-treatment progression assessment circulate micro-ribonucleic acid ( RNA ) circulate marker . IV . To collect buffy coat evaluate steroid transporter . OUTLINE : This dose de-escalation study cabazitaxel . Patients receive cabazitaxel intravenously ( IV ) 1 hour day 1 enzalutamide orally ( PO ) daily ( QD ) day 1-21 ( day 2-21 course 1 ) . Patients also receive prednisone PO twice daily ( BID ) standard care cabazitaxel . Courses repeat every 21 day 6-10 course absence disease progression unacceptable toxicity . Patients may continue enzalutamide PO QD day 1-28 absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day every 6 month 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>Metastatic CRPC least one biopsyaccessible metastasis Evidence prostate cancer progression follow criterion : radiographic PSA criterion , symptomatic progression relate prostate cancer Castrate testosterone level ( &lt; 50 ng/dL ) achieve orchiectomy maintenance luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist Histologic confirmation original prostate cancer diagnosis per institutional standard ; life expectancy great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Leukocytes &gt; = 3,000/mm^3 Absolute neutrophil count &gt; = 1,500/mm^3 Platelets &gt; = 100,000/mm^3 Total bilirubin within normal institutional limit ( &lt; 2 X upper limit normal Gilbert 's disease ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase ( SGOT ) ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase ( SGPT ) ) = &lt; 1.5 X institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance &gt; = 45 mL/min/1.73 m^2 patient creatinine level institutional normal Subject agree use double barrier method birth control course study treatment period enzalutamide and/or cabazitaxel treatment least 3 month study discontinue A doublebarrier method contraception involve use condom combination 1 following : contraceptive sponge , diaphragm , cervical ring spermicidal gel foam Subject vasectomy least 6 month prior start study treatment period whose female sexual partner ( ) 55 year age postmenopausal least 2 year surgically sterile ( tubal ligation , hysterectomy , bilateral oophorectomy ) agree use least condom Ability understand , willingness sign , write informed consent document , well comply study requirement Must appropriate wash ( &gt; 6 halflives ) androgen receptor antagonist , 5 alpha reductase inhibitor ketoconazole prior start cycle 1 ; agent table , washout 2 week Bicalutamide ; approximate halflife : 6 day ; washout period : 36 day Flutamide ; approximate halflife : 6 hour ; washout period : 36 hour Nilutamide approximate halflife : 4 day ; washout period : 24 day Finasteride ; approximate halflife : 8 hour ; washout period : 48 hour Aminoglutethimide ; approximate halflife : 15 hour ; washout period : 4 day Ketoconazole ; approximate halflife : 8 hour ; washout period : 48 hour Prior chemotherapy prostate cancer , unless give neoadjuvantly adjuvantly &gt; 6 month elapse ) Patients may receive investigational agent within last 14 day time treatment start Patients may receive enzalutamide ARN509 ( another androgen receptor antagonist ) past Patients may receive cabazitaxel past Subject clinical sign suggestive high imminent risk pathological fracture , spinal cord compression and/or cauda equina syndrome History severe hypersensitivity reaction ( &gt; = grade 3 ) docetaxel , polysorbate 80 contain drug , capsule component enzalutamide , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 family 3 , subfamily A , polypeptide 4/5 ( 3A4/5 ) ; ( oneweek washout period necessary patient already treatment ) Uncontrolled , intercurrent illness include , limited , ongoing active infection , uncontrolled diabetes , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Subject history seizure condition may predispose seizure include , limited , underlie brain injury , stroke past 6 month , primary brain tumor , brain metastasis , prior seizure Subject medication low seizure threshold discontinue study Aminophylline/theophylline Atypical antipsychotic ( e.g. , clozapine , olanzapine , risperidone , ziprasidone ) Bupropion Lithium Pethidine Phenothiazine antipsychotic ( e.g. , chlorpromazine , mesoridazine , thioridazine ) Tricyclic tetracyclic antidepressant ( e.g. , amitriptyline , desipramine , doxepin , imipramine , maprotiline , mirtazapine ) Tramadol Subject history unexplained loss consciousness transient ischemic attack within 12 month treatment start Subject unwilling stop use herbal supplement affect PSA , saw palmetto prostate cancer ( PC ) SPES Subject another active malignancy nonmelanomatous skin cancer ( unless metastatic ) superficial bladder cancer Must gastrointestinal condition would interfere absorption Subjects may therapies effect hormone level , estrogen , testosterone , ketoconazole study ; however , megestrol hot flash permit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>